These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31905715)

  • 61. Radiological and clinical characterization of the lysosomal storage disorders: non-lipid disorders.
    Parker EI; Xing M; Moreno-De-Luca A; Harmouche E; Terk MR
    Br J Radiol; 2014 Jan; 87(1033):20130467. PubMed ID: 24234586
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Therapy of lysosomal storage diseases: update and perspectives].
    Lara-Aguilar RA; Juárez-Vázquez CI; Medina-Lozano C
    Rev Invest Clin; 2011; 63(6):651-8. PubMed ID: 23650678
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elosulfase alfa.
    Haddley K
    Drugs Today (Barc); 2014 Jul; 50(7):475-83. PubMed ID: 25101330
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Genetic aspects of mucopolysaccharidoses].
    Lacombe D; Germain DP
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S22-6. PubMed ID: 25063380
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
    Shapiro EG; Jones SA; Escolar ML
    Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VI.
    Kumar AB; Masi S; Ghomashchi F; Chennamaneni NK; Ito M; Scott CR; Turecek F; Gelb MH; Spacil Z
    Clin Chem; 2015 Nov; 61(11):1363-71. PubMed ID: 26369786
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Expression of genes involved in apoptosis is dysregulated in mucopolysaccharidoses as revealed by pilot transcriptomic analyses.
    Brokowska J; Pierzynowska K; Gaffke L; Rintz E; Węgrzyn G
    Cell Biol Int; 2021 Mar; 45(3):549-557. PubMed ID: 32125037
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network.
    Salazar DA; Rodríguez-López A; Herreño A; Barbosa H; Herrera J; Ardila A; Barreto GE; González J; Alméciga-Díaz CJ
    Mol Genet Metab; 2016 Feb; 117(2):129-39. PubMed ID: 26276570
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lysosomal storage disorders affecting the heart: a review.
    Nair V; Belanger EC; Veinot JP
    Cardiovasc Pathol; 2019; 39():12-24. PubMed ID: 30594732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Alkaline Phosphatase Activity Induction in Human Spleen Sinuses in Storage Diseases.
    Elleder M
    Virchows Arch B Cell Pathol Incl Mol Pathol; 1979 Dec; 32(1):89-92. PubMed ID: 45156
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacological chaperoning: a primer on mechanism and pharmacology.
    Leidenheimer NJ; Ryder KG
    Pharmacol Res; 2014 May; 83():10-9. PubMed ID: 24530489
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Complex Changes in the Efficiency of the Expression of Many Genes in Monogenic Diseases, Mucopolysaccharidoses, May Arise from Significant Disturbances in the Levels of Factors Involved in the Gene Expression Regulation Processes.
    Cyske Z; Gaffke L; Pierzynowska K; Węgrzyn G
    Genes (Basel); 2022 Mar; 13(4):. PubMed ID: 35456399
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
    Alméciga-Diaz CJ; Hidalgo OA; Olarte-Avellaneda S; Rodríguez-López A; Guzman E; Garzón R; Pimentel-Vera LN; Puentes-Tellez MA; Rojas-Rodriguez AF; Gorshkov K; Li R; Zheng W
    J Med Chem; 2019 Jul; 62(13):6175-6189. PubMed ID: 31188588
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A genetic model of substrate reduction therapy for mucopolysaccharidosis.
    Lamanna WC; Lawrence R; Sarrazin S; Lameda-Diaz C; Gordts PL; Moremen KW; Esko JD
    J Biol Chem; 2012 Oct; 287(43):36283-90. PubMed ID: 22952226
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Chemotactic activity of fibroblasts in mucopolysaccharidoses].
    Albini A; Pontz B; Mensing H; Cantz M; Müller PK
    Padiatr Padol; 1983; 18(3):263-7. PubMed ID: 6412199
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The mucopolysaccharidoses: inborn errors of glycosaminoglycan catabolism.
    Cantz M; Gehler J
    Hum Genet; 1976 Jun; 32(3):233-55. PubMed ID: 820626
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Mucopolysaccharidoses type I and IVA: clinical features and consanguinity in Tunisia.
    Khedhiri S; Chkioua L; Bouzidi H; Dandana A; Ben Turkia H; Miled A; Laradi S
    Pathol Biol (Paris); 2009 Jul; 57(5):392-7. PubMed ID: 18584975
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genetic Base of Behavioral Disorders in Mucopolysaccharidoses: Transcriptomic Studies.
    Pierzynowska K; Gaffke L; Podlacha M; Węgrzyn G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32050523
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mucopolysaccharidosis enzyme production by bone marrow and dental pulp derived human mesenchymal stem cells.
    Jackson M; Derrick Roberts A; Martin E; Rout-Pitt N; Gronthos S; Byers S
    Mol Genet Metab; 2015 Apr; 114(4):584-93. PubMed ID: 25748347
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy.
    Donida B; Marchetti DP; Biancini GB; Deon M; Manini PR; da Rosa HT; Moura DJ; Saffi J; Bender F; Burin MG; Coitinho AS; Giugliani R; Vargas CR
    Biochim Biophys Acta; 2015 May; 1852(5):1012-9. PubMed ID: 25701642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.